Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: A randomized comparison in children with newly diagnosed acute lymphoblastic leukemia

Klinische Padiatrie

Volumn 219, Issue 3, 2007, Pages 134-138

  Escherich, G ^a   Gobel U ^b   Jorch, N ^c   Spaar, H J ^d   Janka Schaub, G E ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Krankenanstalten Gilead GmbH   (Germany)

^d Zentralkrankenhaus Bremen Nord   (Germany)

Author keywords

Acute lymphoblastic leukemia; Cardiotoxicity; Daunorubicin; Leukocyte count

Indexed keywords

ALLOPURINOL; DAUNORUBICIN; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD SMEAR; CELL KILLING; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HUMAN; HYPERURICEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; SINGLE DRUG DOSE; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; INJECTIONS, SPINAL; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; LONG-TERM CARE; MALE; METHOTREXATE; THIOGUANINE; TREATMENT OUTCOME;

EID: 34250791586     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-973849     Document Type: Article

References (29)

1. Holton CP, Lonsdale D, Nora AH, Thurman WG, Vietti TJ. Clinical study of daunomycin (NSC-82151) in children with acute leukemia. Cancer 1968; 22: 1014-1017
2. Holton CP, Vietti TJ, Nora AH, Donaldson MH, Stuckey WJ Jr, Waltkins WL, Lane DM. Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia. N Engl J Med 1969; 280: 171-174
3. Ferrans VJ. Anthracycline cardiotoxicity. Adv Exp Med Biol 1983; 161: 519-532
4. Von Hoff DD, Layard MW, Basa P, Davis HL, von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717
5. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62: 200-208
6. Lipshultz SE, Colon SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815
7. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy - risk factors. Cancer 1977; 39: 1397-1402
8. Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW, Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745-749
9. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139
10. Speyer J, Bottino J, Nidus B, Blum R, Wernz JC, Levin M, Hymes K, Muggia FM. Adriamycin (ADM) 24h infusion: a phase I trial. Proc Am Assoc Cancer Res and ASCO 1981; 22: 363
11. Berrak SUG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA, Benjamin RS. Doxorubicin induced cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous infusion schedules. Oncol reports 2001; 8: 611-614
12. Lipshultz SE, Giatris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Ban RD, Clavell LA, Hurwitz CA, Mohgrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD. Doxorubicin administration by continuous Infusion is not cardioprotctive: The Dana Farber 91-01 Acute Lymphoblastiv Leukemia Protocol. ACO 2002; 20: 1677-1682
13. Ewer MS, Jaffe N, Ried H, Zietz HA, Benjamin RS. Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with single dose infusion administration. MPO 1998; 31: 512-515
14. Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Hem 2004; 124: 463-468
15. Raijmakers R, Speth P, de Witte T, Linssen P, Wessels J, Haanen C. Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM). Br J Cancer 1987; 56: 123-126
16. Bailey-Wood R, Dallimore CM, Whittaker JA. Effect of adriamycin on CFU-GM at plasma concentrations found following therapeutic infusions. Br J Cancer 1984; 50: 351-355
17. Buick RN, Messner HA, Till JE, McCulloch EA. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man. J Nat Cancer Inst 1979; 62: 249-255
18. Eksborg S, Strandler HS, Edsmyr F, Näslund I, Tahvanainen P. Pharmacokinetic study of i.v. infusions of adriamycin. Eur J Clin Pharmacol 1985; 28: 205-212
19. Speth PA, Linssen PC, Boezeman JB, Wessels HM, Haanen C. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion. Cancer Chemother Pharmacol 1987; 20: 311-315
20. Speth PA, Linssen PC, Boezeman JB, Wessels HMC, Haanen C. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother Pharmacol 1987; 20: 305-310
21. DeGregorio MW, Carrera CJ, Klock JC, Pegelow CH, Wilbur J. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia. Cancer Treat Rep 1982; 66: 2085-2088
22. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long term follow up of the trials 85, 89, 92. Leukemia 2000; 14: 2234-2239
23. Hollander M, Wolfe DA. Nonparametric Statistical Methods. John Wiley & Sons, New York, NY 1973
24. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna R, Canetta R, Castellani R, Villa E, Galagher CG, von Melchner H, Hayat M, Ribaud P, de Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, ten Bokkel-Huyninck W, Perevodchikova NI, Manziuk LA, Senn HJ, Mayr AC. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-834
25. Lipshultz SE, Stuart R, Saltan SE, Dalton VM, Mone SM, Gleber RD, Colon SD. Chronic progressiv cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 25: 2629-2636
26. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989; 25: 873-882
27. Chevillard S, Vielh P, Bastion G, Coppey J. A single 24 h contact time with adriamycin provokes the emergence of resistant cells expressing the Gp 170 protein. Anticancer Res 1992; 12: 495-499
28. Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig W-D, Rihem H, Schrappe M. Prognostic impact of age in children and Adolescents with acute lymphoblastic leukemia: Data from the BFM trial 86, 90 and 95. Klin Pädiatr 2005; 217: 310-320
29. Kaatsch P, Blettner M, Spix C, Jürgens H. Follw up of long term surviviors after childhood cancer in Germany. Klin Pädiatr 2005; 217: 169-175